Abstract

Dengue is the most important mosquito-borne viral infection in Sri Lanka causing an enormous social and economic burden in the country. In the absence of therapeutic drugs and the developed vaccines are under investigation, vector control is the best strategy to reduce the disease transmission. Therefore, the development of novel tools to control dengue vector mosquitoes has become the need of the hour. Novaluron is a recently developed Insect Growth Regulator (IGR) which inhibits chitin synthesis in immature stages of insects. The aim of the study was to identify the efficacy of a simple and cost-effective Autocidal Gravid Ovitrap (AGO) developed using Novaluron to control dengue outbreaks in the District of Gampaha, Sri Lanka. Laboratory and semifield experiments were performed to identify the activity range, optimum field dosage, and residual effects of Novaluron following the World Health Organization guidelines, and field experiments were performed in the Ragama Medical Officer of Health (MOH) area. Two study areas 800 m apart were selected and assigned as treated and control areas randomly. In each study area, 30 households were selected randomly. Each household was given two ovitraps, one placed indoors and the other placed outdoors. Mortality and survival counts were recorded separately for one-year time period and data were analyzed using a two-way repeated measures analysis of variance model. During the laboratory experiments, the adult emerging inhibition was 100% in all tested concentrations. The optimum field dosage was 2 ppm and the residual effect was 28 days. In the field experiments, significantly higher mortality counts were recorded in treated areas both indoor- and outdoor-placed AGOs. Two-factor repeated measures ANOVA followed by Tukey's test confirmed that the mean mortality count is high for the developed AGOs both indoor and outdoor settings. The developed AGO can be deployed to control both indoor and outdoor dengue vector mosquito populations, and in dengue-risk areas, the ovitrap will be supportive to local health authorities to enhance the efficiency of future vector control programs.

Highlights

  • Dengue is the most rapidly spreading mosquito-borne viral infection in the tropical and subtropical region of the world

  • The causative agent of the infection is one of the four antigenically distinct serotypes of Dengue Virus (DENV) and the disease transmitted to humans mainly during the blood meal of Aedes (Ae.) mosquitoes predominantly by Ae. aegypti (Linnaeus), an urban vector who almost entirely feed on humans and breed on water-holding artificial containers, and the secondary vector is Ae. albopictus (Skuse)

  • There is neither licensed vaccine nor effective drug available; vector controlling through source reduction is the best strategy to control transmission of dengue in epidemic areas

Read more

Summary

Introduction

Dengue is the most rapidly spreading mosquito-borne viral infection in the tropical and subtropical region of the world. 30,000 dengue infections were reported every year making it a severe health and social burden in the country. The first dengue incidence was reported in Sri Lanka in 1962. In 2017, Sri Lanka experienced the most severe dengue outbreak with 186,101 infections island wide with over 250 dengue-related deaths [3]. There is neither licensed vaccine nor effective drug available; vector controlling through source reduction is the best strategy to control transmission of dengue in epidemic areas. The effectiveness of these programs is questionable mainly due to lack of resources and problems with timely application. Health authorities in Sri Lanka invest their attention recently towards development of novel tools for vector controlling programs as prime requirements

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call